Innovation for Biotherapeutic Comparability with BioPharmaView Software

Significance of the Topic

Biotherapeutic comparability assessments are fundamental to the development, manufacturing and regulation of biologic drugs. Rapid and reliable confirmation of molecular attributes—such as intact mass, post-translational modifications and drug-antibody ratios—ensures product quality and streamlines decision making across development stages and manufacturing sites.

Objectives and Study Overview

The primary goal is to demonstrate how integrated software tools can accelerate and standardize comparability analysis for monoclonal antibodies and antibody-drug conjugates (ADCs). The platform described enables:

• High-throughput intact mass deconvolution for lot-to-lot and biosimilar comparisons.
• Automated peptide mapping workflows, including glycosylation and disulfide bond localization.
• Drug-antibody ratio (DAR) calculations for ADC products.
• Comprehensive reporting and data visualization to support quality control and regulatory filings.

Methodology and Instrumentation

The workflow combines data-independent SWATH® Acquisition on a high-resolution TripleTOF mass spectrometer with BioPharmaView software processing. Key elements include:

• Intact protein analysis in reduced and non-reduced states for molecular weight profiling.
• Automated deconvolution algorithms to extract protein forms and calculate relative abundances.
• Peptide mapping via SWATH Acquisition to achieve full sequence coverage and quantify post-translational modifications.
• Specialized modules for DAR calculation, glycoform ratio computation and disulfide bond assignment.

Main Results and Discussion

Intact mass deconvolution of therapeutic mAb batches revealed consistent glycosylation profiles across multiple lots, with a single lot showing a higher total intensity flagged by built-in pass/fail criteria. ADC analyses demonstrated uniform drug-load distributions and DAR values across four batches. Peptide mapping achieved 100% sequence coverage of adalimumab, enabling precise quantification of oxidation, deamidation and other modifications. Automated disulfide bond localization was confirmed by annotated MS/MS spectra, highlighting the robustness of the algorithms.

The multi-pane interface facilitated side-by-side comparison of processed and raw data, improving confidence in comparability decisions. Batch processing and custom modification libraries reduced manual intervention and analysis time.

Benefits and Practical Applications

Implementing this integrated approach yields several advantages:

• Enhanced throughput: One-click batch processing accelerates intact mass and peptide mapping workflows.
• Standardization: Automated flagging based on user-defined criteria ensures consistent quality assessments across sites.
• Regulatory readiness: Comprehensive reports in multiple formats support documentation for biosimilarity and manufacturing changes.
• Data traceability: Direct links to raw spectra increase transparency and facilitate audit readiness.

Future Trends and Opportunities

Emerging developments in biotherapeutic analytics are likely to focus on:

• Integration of machine learning models for predictive modification profiling and anomaly detection.
• Expansion of data-independent acquisition libraries to cover novel modalities such as bispecifics and fusion proteins.
• Cloud-based collaborative platforms enabling global comparability studies and meta-analysis across laboratories.
• Real-time monitoring of critical quality attributes during continuous manufacturing processes.

Conclusion

The combination of SWATH® Acquisition and specialized software offers a fast, reliable and scalable solution for biotherapeutic comparability. By automating complex deconvolution, peptide mapping and reporting tasks, the approach supports rigorous quality control, accelerates development timelines and enhances confidence in biosimilar and batch consistency evaluations.

Used Instrumentation

• SCIEX TripleTOF mass spectrometer with SWATH® Acquisition capability
• BioPharmaView™ software for intact mass deconvolution and peptide mapping